Spero Therapeutics, Inc. (SPRO)
USD 0.99
(-3.88%)
USD 0.99
(-3.88%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -32.99 Million | -7.73 Million | -64.34 Million | -85.87 Million | -50.02 Million | -39.62 Million |
| Net Income | 22.8 Million | -46.41 Million | -89.75 Million | -78.28 Million | -60.92 Million | -41.66 Million |
| Depreciation & Amortization | 367 Thousand | 869 Thousand | 646 Thousand | 761 Thousand | 750 Thousand | 409 Thousand |
| Deferred income taxes | -8.36 Million | - | 60 Thousand | -362 Thousand | -808 Thousand | - |
| Stock-based compensation | 7.93 Million | 9.12 Million | 9.43 Million | 4.88 Million | 3.77 Million | 2.74 Million |
| Change in working capital | -70.37 Million | 22.08 Million | 12.9 Million | -13.39 Million | 6.83 Million | -1.07 Million |
| Other non-cash items | 14.64 Million | 6.6 Million | 2.37 Million | 513 Thousand | 356 Thousand | -50 Thousand |
| Investing Cash Flow | - | 33.8 Million | 7.67 Million | 10.47 Million | 29.53 Million | -83.15 Million |
| Investments in PPE | - | - | 39 Thousand | -157 Thousand | -314 Thousand | -2.43 Million |
| Acquisitions | - | - | -39 Thousand | -10.62 Million | -29.84 Million | 83.15 Million |
| Investment purchases | - | -26.97 Million | -43.91 Million | -45.72 Million | -88.99 Million | -130.17 Million |
| Sales/Maturities of investments | - | 60.77 Million | 51.54 Million | 56.35 Million | 118.83 Million | 49.45 Million |
| Other Investing Activities | - | 33.8 Million | 39 Thousand | 10.62 Million | 29.84 Million | -83.15 Million |
| Financing Cash Flow | 221 Thousand | -29.55 Million | 84.05 Million | 130.88 Million | 16.14 Million | 69.52 Million |
| Debt repayment | - | -54.48 Million | -47.48 Million | -333 Thousand | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | 10.27 Million | 27.53 Million | - | - | - |
| Common Stock Issuance | 221 Thousand | 24.93 Million | 36.57 Million | 78.66 Million | 15.79 Million | 70.5 Million |
| Other Financing Activities | 221 Thousand | -29.55 Million | 84.05 Million | 52.55 Million | 350 Thousand | -977 Thousand |
| Accounts receivables | -461 Thousand | 1.54 Million | 3.83 Million | 2.17 Million | -7.08 Million | 1.4 Million |
| Accounts payables | 761 Thousand | -484 Thousand | -53 Thousand | -2.97 Million | 564 Thousand | 84 Thousand |
| Inventory | - | -1.54 Million | -3.83 Million | -2.17 Million | 7.08 Million | - |
| Other working capital | -70.67 Million | 22.57 Million | 12.95 Million | -10.41 Million | 6.26 Million | -1.15 Million |
| Cash at beginning of period | 109.1 Million | 112.58 Million | 85.2 Million | 29.73 Million | 34.08 Million | 87.33 Million |
| Cash at end of period | 76.33 Million | 109.1 Million | 112.58 Million | 85.2 Million | 29.73 Million | 34.08 Million |
| Capital Expenditure | - | - | 39 Thousand | -157 Thousand | -314 Thousand | -2.43 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -32.77 Million | -3.47 Million | 27.37 Million | 55.47 Million | -4.35 Million | -53.25 Million |
| Free Cash Flow | -32.99 Million | -7.73 Million | -64.3 Million | -86.02 Million | -50.33 Million | -42.06 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -17.86 Million | -12.66 Million | 51.19 Million | 22.8 Million | -3.2 Million | -11.91 Million |
| Depreciation & Amortization | 2000.00 | - | 38 Thousand | 367 Thousand | 108 Thousand | 108 Thousand |
| Deferred income taxes | - | - | -354 Thousand | -8.36 Million | 5.3 Million | - |
| Stock-based compensation | 2.11 Million | 2.02 Million | 1.99 Million | 7.93 Million | 1.9 Million | 1.85 Million |
| Change in working capital | -3.25 Million | 16.32 Million | -70.96 Million | -70.37 Million | 11.55 Million | -8.85 Million |
| Other non-cash items | 4.39 Million | -19.27 Million | 602 Thousand | 14.64 Million | 244 Thousand | 240 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | - | 1000.00 | 221 Thousand | 220 Thousand | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 1000.00 | 221 Thousand | 220 Thousand | - |
| Other Financing Activities | - | - | 1000.00 | 221 Thousand | 220 Thousand | - |
| Accounts receivables | -1.65 Million | 19.86 Million | 1.44 Million | -461 Thousand | -901 Thousand | -223 Thousand |
| Accounts payables | -370 Thousand | 1.68 Million | 275 Thousand | 761 Thousand | -207 Thousand | 727 Thousand |
| Inventory | - | - | -1.9 Million | - | 901 Thousand | 223 Thousand |
| Other working capital | -1.23 Million | -5.21 Million | -72.68 Million | -70.67 Million | 11.76 Million | -9.58 Million |
| Cash at beginning of period | 82.27 Million | 76.33 Million | 93.82 Million | 109.1 Million | 77.69 Million | 96.25 Million |
| Cash at end of period | 63.52 Million | 82.27 Million | 76.33 Million | 76.33 Million | 93.82 Million | 77.69 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -18.74 Million | 5.93 Million | -17.49 Million | -32.77 Million | 16.13 Million | -18.56 Million |
| Free Cash Flow | -18.74 Million | 5.93 Million | -17.49 Million | -32.99 Million | 15.91 Million | -18.56 Million |
601108
300068
SNC
IVREF
NBRY
ZONE